Random insertion of mcherry into VP3 domain of adeno-associated virus yields fluorescent capsids with no loss of infectivity

Molecular Therapy Nucleic Acids

Volumn 1, Issue 11, 2012, Pages

  Judd, Justin ^a   Wei, Fang ^a   Nguyen, Peter Q ^b,d   Tartaglia, Lawrence J ^c   Agbandje Mckenna, Mavis ^c   Silberg, Jonathan J ^b   Suh, Junghae ^a  

^a Rice University   (United States)

^b RICE UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

AAV; directed evolution; random domain insertion

Indexed keywords

ADENOVIRUS VECTOR; DEOXYRIBONUCLEASE; FLUORESCENT DYE; PROTEIN MCHERRY; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ARTICLE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOLECULAR LIBRARY; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; RANDOM PEPTIDE INSERTION; STRUCTURE ANALYSIS; VIRUS CAPSID; VIRUS INFECTIVITY;

EID: 84869390793     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.46     Document Type: Article

References (48)

1. Kotin, RM, Siniscalco, M, Samulski, RJ, Zhu, XD, Hunter, L, Laughlin, CA et al. (1990). Site-specifc integration by adeno-associated virus. Proc Natl Acad Sci USA 87: 2211-2215.
2. Samulski, RJ, Zhu, X, Xiao, X, Brook, JD, Housman, DE, Epstein, N et al. (1991). Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10: 3941-3950. (Pubitemid 21905423)
3. Sonntag, F, Schmidt, K and Kleinschmidt, JA (2010). A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci USA 107: 10220-10225
4. Summerford, C and Samulski, RJ (1998). Membrane-associated heparan sulfate proteo-glycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438-1445 (Pubitemid 28116931)
5. Qing, K, Mah, C, Hansen, J, Zhou, S, Dwarki, V and Srivastava, A (1999). Human fbroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5: 71-77. (Pubitemid 29051001)
6. Kaplitt, MG, Leone, P, Samulski, RJ, Xiao, X, Pfaff, DW, O'Malley, KL et al. (1994). Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8: 148-154. (Pubitemid 24308362)
7. Zaiss, AK, Liu, Q, Bowen, GP, Wong, NC, Bartlett, JS and Muruve, DA (2002). Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 76: 4580-4590 (Pubitemid 34309593)
8. Yang, Q, Mamounas, M, Yu, G, Kennedy, S, Leaker, B, Merson, J et al. (1998). Develop-ment of novel cell surface CD34-targeted recombinant adeno-associated virus vectors for gene therapy. Hum Gene Ther 9: 1929-1937. (Pubitemid 28439098)
9. Girod, A, Ried, M, Wobus, C, Lahm, H, Leike, K, Kleinschmidt, J et al. (1999). Genetic capsid modifcations allow effcient re-targeting of adeno-associated virus type 2. Nat Med 5: 1438.
10. Müller, OJ, Kaul, F, Weitzman, MD, Pasqualini, R, Arap, W, Kleinschmidt, JA et al. (2003). Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21: 1040-1046. (Pubitemid 37064733)
11. Seisenberger, G, Ried, MU, Endress, T, Büning, H, Hallek, M and Bräuchle, C (2001). Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 294: 1929-1932. (Pubitemid 33101590)
12. Le, HT, Yu, QC, Wilson, JM and Croyle, MA (2005). Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J Control Release 108: 161-177. (Pubitemid 41476684)
13. Lee, GK, Maheshri, N, Kaspar, B and Schaffer, DV (2005). PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng 92: 24-34. (Pubitemid 41657584)
14. Maheshri, N, Koerber, JT, Kaspar, BK and Schaffer, DV (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24: 198-204. (Pubitemid 43221704)
15. Joo, KI, Fang, Y, Liu, Y, Xiao, L, Gu, Z, Tai, A et al. (2011). Enhanced real-time monitoring of adeno-associated virus traffcking by virus-quantum dot conjugates. ACS Nano 5: 3523-3535.
16. Wei, F, McConnell, KI, Yu, TK and Suh, J (2012). Conjugation of paclitaxel on adeno-associated virus (AAV) nanoparticles for co-delivery of genes and drugs. Eur J Pharm Sci 46: 167-172
17. Bartlett, JS, Kleinschmidt, J, Boucher, RC and Samulski, RJ (1999). Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecifc F(ab'gamma)2 antibody. Nat Biotechnol 17: 181-186. (Pubitemid 29072544)
18. Warrington, KH Jr, Gorbatyuk, OS, Harrison, JK, Opie, SR, Zolotukhin, S and Muzyczka, N (2004). Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol 78: 6595-6609 (Pubitemid 38715956)
19. Lux, K, Goerlitz, N, Schlemminger, S, Perabo, L, Goldnau, D, Endell, J et al. (2005). Green fuorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear traffcking. J Virol 79: 11776-11787. (Pubitemid 41279296)
20. Rabinowitz, JE, Xiao, W and Samulski, RJ (1999). Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265: 274-285. (Pubitemid 30022222)
21. Wu, P, Xiao, W, Conlon, T, Hughes, J, Agbandje-McKenna, M, Ferkol, T et al. (2000). Mu-tational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 74: 8635-8647. (Pubitemid 30666714)
22. Kronenberg, S, Böttcher, B, von der Lieth, CW, Bleker, S and Kleinschmidt, JA (2005). A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol 79: 5296-5303 (Pubitemid 40548198)
23. Perabo, L, Büning, H, Kofer, DM, Ried, MU, Girod, A, Wendtner, CM et al. (2003). In vitro selection of viral vectors with modifed tropism: the adeno-associated virus display. Mol Ther 8: 151-157. (Pubitemid 36939306)
24. Li, W, Asokan, A, Wu, Z, Van Dyke, T, DiPrimio, N, Johnson, JS et al. (2008). Engineering and selection of shuffed AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 16: 1252-1260 (Pubitemid 351866056)
25. Koerber, JT and Schaffer, DV (2008). Transposon-based mutagenesis generates diverse adeno-associated viral libraries with novel gene delivery properties. Methods Mol Biol 434: 161-170.
26. Koerber, JT, Jang, JH, Yu, JH, Kane, RS and Schaffer, DV (2007). Engineering adeno-associated virus for one-step purifcation via immobilized metal affnity chromatography. Hum Gene Ther 18: 367-378. (Pubitemid 46709348)
27. Guntas, G and Ostermeier, M (2004). Creation of an allosteric enzyme by domain insertion. J Mol Biol 336: 263-273. (Pubitemid 38102347)
28. Ried, MU, Girod, A, Leike, K, Büning, H and Hallek, M (2002). Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector re-targeting to specifc cell surface receptors. J Virol 76: 4559-4566 (Pubitemid 34309591)
29. Hida, K, Won, SY, Di Pasquale, G, Hanes, J, Chiorini, JA and Ostermeier, M (2010). Sites in the AAV5 capsid tolerant to deletions and tandem duplications. Arch Biochem Biophys 496: 1-8.
30. Shaner, NC, Campbell, RE, Steinbach, PA, Giepmans, BN, Palmer, AE and Tsien, RY (2004). Improved monomeric red, orange and yellow fuorescent proteins derived from Discosoma sp. red fuorescent protein. Nat Biotechnol 22: 1567-1572. (Pubitemid 40039460)
31. Gerth, ML, Patrick, WM and Lutz, S (2004). A second-generation system for unbiased reading frame selection. Protein Eng Des Sel 17: 595-602. (Pubitemid 39576486)
32. Shu, X, Shaner, NC, Yarbrough, CA, Tsien, RY and Remington, SJ (2006). Novel chro-mophores and buried charges control color in mFruits. Biochemistry 45: 9639-9647. (Pubitemid 44257411)
33. Borovjagin, AV, McNally, LR, Wang, M, Curiel, DT, MacDougall, MJ and Zinn, KR (2010). Noninvasive monitoring of mRFP1-and mCherry-labeled oncolytic adenoviruses in an or-thotopic breast cancer model by spectral imaging. Mol Imaging 9: 59-75.
34. Gigout, L, Rebollo, P, Clement, N, Warrington, KH Jr, Muzyczka, N, Linden, RM et al. (2005). Altering AAV tropism with mosaic viral capsids. Mol Ther 11: 856-865 (Pubitemid 40724104)
35. Muralidhar, S, Becerra, SP and Rose, JA (1994). Site-directed mutagenesis of adeno-as-sociated virus type 2 structural protein initiation codons: effects on regulation of synthesis and biological activity. J Virol 68: 170-176
36. Gao, G, Alvira, MR, Somanathan, S, Lu, Y, Vandenberghe, LH, Rux, JJ et al. (2003). Adeno-associated viruses undergo substantial evolution in primates during natural infec-tions. Proc Natl Acad Sci USA 100: 6081-6086. (Pubitemid 36576934)
37. Shi, W, Arnold, GS and Bartlett, JS (2001). Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 12: 1697-1711. (Pubitemid 32911637)
38. Govindasamy, L, Padron, E, McKenna, R, Muzyczka, N, Kaludov, N, Chiorini, JA et al. (2006). Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol 80: 11556-11570. (Pubitemid 44788870)
39. Ding, W, Zhang, LN, Yeaman, C and Engelhardt, JF (2006). rAAV2 traffcs through both the late and the recycling endosomes in a dose-dependent fashion. Mol Ther 13: 671-682
40. Asokan, A, Johnson, JS, Li, C and Samulski, RJ (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther 15: 1618-1622.
41. Grieger, JC, Johnson, JS, Gurda-Whitaker, B, Agbandje-McKenna, M and Samulski, RJ (2007). Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fvefold pore mutant virions. J Virol 81: 7833-7843. (Pubitemid 47101469)
42. Wu, Z, Yang, H and Colosi, P (2010). Effect of genome size on AAV vector packaging. Mol Ther 18: 80-86.
43. Xie, Q, Bu, W, Bhatia, S, Hare, J, Somasundaram, T, Azzi, A et al. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 99: 10405-10410.
44. Boucas, J, Lux, K, Huber, A, Schievenbusch, S, von Freyend, MJ, Perabo, L et al. (2009). Engineering adeno-associated virus serotype 2-based targeting vectors using a new inser-tion site-position 453-and single point mutations. J Gene Med 11: 1103-1113.
45. Gigout, L, Rebollo, P, Clement, N, Warrington, KH Jr, Muzyczka, N, Linden, RM et al. (2005). Altering AAV tropism with mosaic viral capsids. Mol Ther 11: 856-865 (Pubitemid 40724104)
46. Levy, HC, Bowman, VD, Govindasamy, L, McKenna, R, Nash, K, Warrington, K et al. (2009). Heparin binding induces conformational changes in Adeno-associated virus sero-type 2. J Struct Biol 165: 146-156.
47. Rabinowitz, JE, Bowles, DE, Faust, SM, Ledford, JG, Cunningham, SE and Samulski, RJ (2004). Cross-dressing the virion: the transcapsidation of adeno-associated virus sero-types functionally defnes subgroups. J Virol 78: 4421-4432. (Pubitemid 38501062)
48. Ho, SN, Hunt, HD, Horton, RM, Pullen, JK and Pease, LR (1989). Site-directed muta-genesis by overlap extension using the polymerase chain reaction. Gene 77: 51-59. (Pubitemid 19125653)